— Reveals Plug and Play, Low Cost, No Scar, Scalable Enzymatic Synthesis 3.0 — — Partners with PacBio, Singular Genomics Enabling New Sequencing Platforms — January 10, 2022 08:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has developed an innovative, low cost, scarless and scalable enzymatic DNA synthesis process. With these comprehensive capabilities in synthesis, Twist offers ..read more

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies Beam will receive an upfront payment of $300 million, be eligible to receive future milestone payments of up to $1.05 billion for a potential total consideration of up to $1.35 billion Beam may opt into a global co-development and co-commercialization agreement for one program Research and development activities aim to advance poten ..read more

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Aanika Biosciences, a growing biotech start-up using edible microbial tags to improve food safety, today announced a strategic partnership that will enable faster identification of outbreak sources, reduce incidents of fresh produce contamination and minimize the impact of food borne illness related recalls. In this partnership, Aanika will use Berkeley Lights’ high-throughput, functional screening service to rapidly identify and optimize functional, antimicrobial pep ..read more

Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement January 10, 2022 02:30 AM Eastern Standard Time BERLIN & BRISBANE, Calif.–(BUSINESS WIRE)–Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration and option agreement ..read more

Inscripta®, the Digital Genome Engineering Company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, has adopted the Onyx® Genome Engineering Platform in its foundries. BOULDER, CO. — January 10, 2022 — Inscripta®, the Digital Genome Engineering Company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, has adopted the Onyx® Genome Engineering Platform in its foundries. Ginkgo’s investment is part of its commitment to integrating cutt ..read more

Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technology Pfizer’s successful development and commercialization of licensed products could result in milestone payments in excess of $100 million SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (NASDAQ: DNAY), a leader in the development of automated solutions for on-demand synthesis of genes and mRNA, today announced a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA’s novel EDS tec ..read more

Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicity WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ —  Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for ..read more

Collaboration to leverage Absci’s Deep Learning-Enabled Drug Creation and Bionic Protein technologies VANCOUVER, Wash., Jan. 07, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci’s AI-powered Integrated Drug Creation Platform. Under the collaboration, Absci will deploy its Bionic Protein non-standard amino acid ..read more

January 05, 2022 08:00 AM Eastern Standard Time BOULDER, Colo.–(BUSINESS WIRE)–Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather, PhD, to serve on its Board of Directors. Dr. Prather is currently the Arthur D. Little Professor and Executive Officer of the Department of Chemical Engineering at MIT. “We are very excited to have Kris join our board. She brings a distinguished scientific background and a thoughtful perspective on the field of synthetic biology that will be invaluable to Inscripta and our customers,” said Sri Kosa ..read more

BOSTON and CINCINNATI, Jan. 6, 2022 /PRNewswire/ — Optimvia, a biotechnology company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo’s cell and enzyme engineering platform, as well as its fer ..read more